Actionable gene expression-based patient stratification for molecular targeted therapy in hepatocellular carcinoma.

Kwon, Jung-Hee; Lee, Namgyu; Park, Jin Young; Yu, Yun Suk; Kim, Jin Pyo; Shin, Ji Hye; Kim, Dong-Sik; Joh, Jae Won; Kim, Dae Shick; Choi, Kwan Yong; Kang, Koo-Jeong; Kim, Gundo; Moon, Young Ho; Wang, Hee Jung
PloS one
2013NA ; 8 ( 6 ) :e64260.
저자 상세정보
Kwon, Jung-Hee -
Lee, Namgyu -
Park, Jin Young -
Yu, Yun Suk -
Kim, Jin Pyo -
Shin, Ji Hye -
Kim, Dong-Sik -
Joh, Jae Won -
Kim, Dae Shick -
Choi, Kwan Yong -
Kang, Koo-Jeong -
Kim, Gundo -
Moon, Young Ho -
Wang, Hee Jung -
ABSTRACT
BACKGROUND: The effectiveness of molecular targeted agents is modest in hepatocellular carcinoma (HCC). Efficacy of molecular targeted therapies has been better in cancer patients with high expression of actionable molecules defined as cognate target molecules. However, patient stratification based on the actionable molecules dictating the effectiveness of targeted drugs has remained understudied in HCC. EXPERIMENTAL DESIGN &

RESULTS: Paired tumor and non-tumoral tissues derived from a total of 130 HCC patients were studied. Real-time RT-PCR was used to analyze the mRNA expression of actionable molecules in the tissues. mRNA levels of EGFR, VEGFR2, PDGFR棺, FGFR1, and mTOR were up-regulated in tumors compared to non-tumors in 35.4, 42.3, 61.5, 24.6, and 50.0% of patients, respectively. Up-regulation of EGFR was observed at early stage and tended to gradually decrease toward late stages (BCLC stage A: 41.9%; B: 30.8%; C: 17.6%). Frequency of VEGFR2 expression in tumors at stage C was lower than that in the other stages (BCLC stage A: 45.9%; B: 41.0%; C: 29.4%). PDGFR棺 and mTOR were observed to be up-regulated in more than 50% of tumors in all the stages whereas FGFR1 was up-regulated in only about 20% of HCC irrespective of stages. A cluster analysis of actionable gene expression revealed that HCC can be categorized into different subtypes that predict the effectiveness of molecular targeted agents and combination therapies in clinical trials. Analysis of in vitro sensitivity to sorafenib demonstrated that HCC cells with up-regulation of PDGFR棺 and c-Raf mRNA are more susceptible to sorafenib treatment in a dose and time-dependent manner than cells with low expression of the genes.

CONCLUSIONS: mRNA expression analysis of actionable molecules could provide the rationale for new companion diagnostics-based therapeutic strategies in the treatment of HCC.
na
MESH
Adult, Aged, Antineoplastic Agents/*pharmacology, Carcinoma, Hepatocellular/drug therapy/*genetics/pathology, Cell Line, Tumor, Cluster Analysis, Female, Gene Expression Regulation, Neoplastic/*drug effects, Humans, Liver Neoplasms/drug therapy/*genetics/pathology, Male, Middle Aged, *Molecular Targeted Therapy, Neoplasm Staging, Niacinamide/analogs & derivatives/pharmacology, Phenylurea Compounds/pharmacology, Protein Kinase Inhibitors/pharmacology, RNA, Messenger/genetics, *Transcriptome
링크

주제코드
주제명(Target field)
연구대상(Population)
연구참여(Sample size)
대상성별(Gender)
질병특성(Condition Category)
연구환경(Setting)
연구설계(Study Design)
연구기간(Period)
중재방법(Intervention Type)
중재명칭(Intervention Name)
키워드(Keyword)
유효성결과(Recomendation)
This study investigated mRNA expression for 5 actionable molecules (EGFR, VEGFR2, PDGFRβ, FGFR1, and mTOR) in 130 HCC and matched non-tumoral tissues.
연구비지원(Fund Source)
근거수준평가(Evidence Hierarchy)
출판년도(Year)
참여저자수(Authors)
대표저자
DOI
10.1371/journal.pone.0064260
KCD코드
ICD 03
건강보험코드